受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | Hexadecylphosphocholine | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
||||
化学式 | C21H46NO4P |
||||||
分子量 | 407.57 | CAS No. | 58066-85-6 | ||||
Solubility (25°C)* | 体外 | Water | 82 mg/mL (201.19 mM) | ||||
Ethanol | 82 mg/mL (201.19 mM) | ||||||
DMSO | Insoluble | ||||||
体内 (毎回新しく調製した物を用意してください) |
|
||||||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Miltefosine (Hexadecylphosphocholine) inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes. |
---|---|
in vitro | Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi. Miltefosine inhibits PKC from NIH3T3 cells in cell-free extracts with a IC50 of about 7 μM.[1] Miltefosine targets HIV infected macrophages, which play a role in vivo as long-lived HIV-1 reservoirs. Miltefosine acts by inhibiting the PI3K/Akt pathway, thus removing the infected macrophages from circulation, without affecting healthy cells.[2] Miltefosine inhibits the PI3K/Akt survival pathway in carcinoma cell lines.[3] Miltefosine causes skeletal muscle insulin resistance in vitro by interfering with the insulinsignalling pathway and inhibiting insulin-stimulated glucose uptake. Miltefosine inhibits insulin-stimulated Akt phosphorylation in a dose-dependent manner with 75% inhibition at 40 μM and 98% inhibition at 60 μM.[4] |
in vivo | Miltefosine inhibits anti-IgE induced histamine release from human skin mast cells. Miltefosine can reduce cytokines IL-1β, IL-4, and IL-6 in certain skin tissue cells and also strongly impede the esterification of cholesterol. [5] |
細胞アッセイ | 細胞株 | BCLM, VG-1, BC-1, and BCBL-1 PEL cell lines |
---|---|---|
濃度 | 10, 20, 30, 40, and 50μM | |
反応時間 | 3 days | |
実験の流れ | 2 × 105 PEL cells are treated with the therapeutic compounds at the indicated doses or with appropriate vehicle as a negative control. Cells are followed for 96 hours, and cell viability is determined by trypan blue exclusion performed in quadruplicate. | |
動物実験 | 動物モデル | BC-1 cells xenografted NOD-SCID mice |
投薬量 | 50 mg/kg | |
投与方法 | i.p. |
, , Biochem Biophys Res Commun, 2016, 469(4):1034-40.
, , Biochem Biophys Res Commun, 2016, 469(4):1034-40.
FAT10 Combined with Miltefosine Inhibits Mitochondrial Apoptosis and Energy Metabolism in Hypoxia-Induced H9C2 Cells by Regulating the PI3K/AKT Signaling Pathway [ Evid Based Complement Alternat Med, 2022, 2022:4388919] | PubMed: 36034957 |
Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs [ Biomed Chromatogr, 2022, e5519.] | PubMed: 36208186 |
FOXM1-mediated activation of phospholipase D1 promotes lipid droplet accumulation and reduces ROS to support paclitaxel resistance in metastatic cancer cells [ Free Radic Biol Med, 2021, S0891-5849(21)00821-2] | PubMed: 34808333 |
CORO1C is Associated With Poor Prognosis and Promotes Metastasis Through PI3K/AKT Pathway in Colorectal Cancer [ Front Mol Biosci, 2021, 8:682594] | PubMed: 34179087 |
The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis. [ Cell Oncol (Dordr), 2020, 8] | PubMed: 32382996 |
Inhibition of MEIS3 Generates Cetuximab Resistance through c-Met and Akt [ Biomed Res Int, 2020, 2020:2046248] | PubMed: 33376716 |
Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo [ J Clin Med, 2019, 8(6)] | PubMed: 31238539 |
LMO4 promotes the invasion and proliferation of gastric cancer by activating PI3K-Akt-mTOR signaling [ Am J Transl Res, 2019, 11(10):6534-6543] | PubMed: 31737204 |
Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen Balamuthia mandrillaris. [ mBio, 2018, 9(5)] | PubMed: 30377287 |
Repurposing the quinoline antibiotic nitroxoline to treat infections caused by the brain-eating amoeba Balamuthia mandrillaris [ bioRxiv, 2018, 10.1101/331785] | PubMed: N/A |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。